We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


GENEART Awarded two US Patents for Successfully Tested HIV Vaccines

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "GENEART Awarded two US Patents for Successfully Tested HIV Vaccines"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

The GENEART AG announces the award of the patents US 7,332,588 and US 7,323,557 titled "Genome of the HIV-1 inter-subtype (C/B') and use thereof" by the United States Patent and Trademark Office. The above-mentioned patents protect the use of specific custom-designed HIV gene sequences for the development as therapeutics or vaccines.

Recently, the now patent-protected gene sequences have been tested as HIV vaccine candidates on 40 test persons by the EuroVacc Foundation in a phase I clinical trial. The trial has turned out to be successful. The results of this study have been published in "The Journal of Experimental Medicine" (Vol. 205, 63-77).

In the trial, the prophylactic vaccination proved to be safe and well tolerated, and it triggered a strong and lasting immune response in 90 % of the vaccinated test persons in London and Lausanne. As the licensor, GENEART provided the patented gene sequences (structural design) for the tested vaccines.

The synthetic genes were custom-designed by the scientists at GENEART and the University of Regensburg. These genes serve as the basis for the vaccine candidates, which are used in the so-called "prime boost" procedure as naked DNA (DNA-HIV-C), and with a genetically modified small pox vaccine (NYVAC-HIV-C) as a carrier system.

The further clinical I/II studies with 120 test persons in Lausanne, London, Paris and Regensburg started already in the beginning of 2008, under the patronage of the European research cluster EuroVacc.